May 25 2011 - Texas Oncology-Tyler and MFH-Tyler partner with International Genomics Consortium
For Immediate Release
May 25, 2011
For more information:
Public Information Officer
Trinity Mother Frances
Joe Paulauskis Ph.D.
International Genomics Consortium
TEXAS ONCOLOGY-TYLER AND MOTHER FRANCES HOSPITAL-TYLER PARTNER WITH THE INTERNATIONAL GENOMICS CONSORTIUM AS A KEY NETWORK TISSUE SOURCE SITE FOR THE NIH'S “THE CANCER GENOME ATLAS PROJECT”
Tyler, TX – Texas Oncology-Tyler and Mother Frances Hospital-Tyler announced today that they have agreed to collaborate with The International Genomics Consortium (IGC) to serve as a critical network tissue source site (TSS) to provide cancer tissue samples for analysis in the National Institutes of Health’s (NIH’s) historic project “The Cancer Genome Atlas project (TCGA)”. Mother Frances will provide cancer tissue samples under uniform and standardized conditions and also collect specific long-term clinical outcome data to facilitate research into the underlying cancer mechanisms.
IGC’s expression project for Oncology (expO) has combined its network and mission with TCGA to help create a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing. The overarching goal of TCGA is to improve the ability to diagnose, treat and prevent cancer. TCGA is one of the largest initiatives to date to analyze such a wide array of cancers with so many different genomic analyses ranging from sequencing to methylation studies. The genomic blueprints of each cancer will be available on the web for all scientists to have access to for translational discoveries. TCGA plans to analyze 500 tumors from each cancer type studied by the program and will provide the clinically annotated outcome data along with the complete genomic analysis on the web, free of any intellectual property restrictions. IGC plans to retain a portion of each sample that it provides to TCGA, if available, to expedite translational discoveries to help patient care, in work separate from TCGA. Additional information on TCGA may be found at http://cancergenome.nih.gov/.
"There have been great advancements in cancer care in the last two decades, but The Cancer Genome Atlas project holds the potential to deliver truly amazing discoveries, treatments and cures. This may be the most significant cancer research project to date. Texas Oncology-Tyler and Mother Frances are ready to serve in the important role of being one of only 12 sites in the U.S. for this project," said Donald A. Richards, MD, Ph.D., oncologist, Texas Oncology-Tyler, and principal investigator of the local Cancer Genome Atlas project. “We look forward to supporting The Cancer Genome Atlas project and other initiatives at IGC through our research efforts here at Mother Frances and continuing not only to provide world class patient care, but also facilitating ground breaking cancer research.” said Laura Owen, FACHE, CEO, Mother Frances Hospital-Tyler.
“We are honored to partner with Texas Oncology-Tyler and Mother Frances Hospital on this historic NCI initiative to join in the fight against cancer,” said Robert Penny, M.D., Ph.D., IGC’s CEO and Principle Investigator for both the TSS and BCR components of TCGA.
David Mallery, JD, MBA, IGC’s President noted, “Together with Texas Oncology-Tyler and Mother Frances, we look forward to providing the critical biospecimens and data necessary to facilitate translational research.”
IGC thanks the National Cancer Institute, the National Human Genome Research Institute, Maricopa County, the City of Phoenix, Caris Life Sciences, Science Foundation Arizona, the Flinn Foundation as well as many of the pharmaceutical companies that have provided financial and leadership support to IGC and our initiatives in the past.
About Texas Oncology-Tyler
Texas Oncology-Tyler is one of the leaders among the members of the Texas Oncology network in terms of cancer research. The center has contributed to the development of 43 of the most recently approved therapies for cancer care in the United States. On average, Texas Oncology-Tyler has more than 60 trials available for eligible patients. In 2010, Texas Oncology-Tyler was the top enrolling location for research accruals within US Oncology, the nation's largest community-based cancer research network.
About Trinity Mother Frances Hospitals and Clinics
Trinity Mother Frances Hospitals and Clinics includes The Louis and Peaches Owen Heart Hospital, Mother Frances Hospital-Tyler, Mother Frances Hospital-Jacksonville, Mother Frances Hospital-Winnsboro, Trinity Mother Frances Rehabilitation Hospital, affiliated with HealthSouth, Tyler ContinueCARE Hospital, a long-term acute care facility, and Trinity Clinic. Trinity Clinic is the area's preferred multispecialty medical group, with over 280 physicians and mid-level providers representing 38 specialties in 36 clinic locations serving east Texas. For more information on services available through Trinity Mother Frances Hospitals and Clinics, visit tmfhc.org.
The International Genomics Consortium (IGC) is a non-profit medical research foundation established to expand upon the discoveries of the Human Genome Project and other systematic sequencing efforts by combining world-class genomic research, bioinformatics, and diagnostic technologies in the fight against cancer and other complex genetic diseases. IGC serves numerous common, unmet needs including: the standardization of the collection of properly consented tissues of interest, the molecular characterization of these tissues, and standardization in the representation of these results. IGC participates in the transition of genomic discoveries to improve patient care and increase the speed in which new diagnostic, prognostic and predictive testing, and new drug and treatment regimens are developed. For more information, visit www.intgen.org.
# # #